header logo image


Page 35«..1020..34353637..4050..»

Archive for the ‘Biotechnology’ Category

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results – GlobeNewswire

Thursday, March 12th, 2020

SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2019. Unity issued a press release providing pipeline and business updates on February 25, 2020.

Fourth Quarter and Full Year 2019 Financial Results

Cash, cash equivalents and investments totaled $125.0 million as of December 31, 2019 compared with $171.1 million as of December 31, 2018.

Operating loss for the twelve months ended December 31, 2019 was $89.7 million compared to $79.5 million for the twelve months ended December 31, 2018. Cash used in operations during the year ended 2019 was $72.4 million compared to $56.6 million for the year ended 2018. Total operating loss for the three months ended December 31, 2019 was $23.1 million compared to $22.8 million for the fourth quarter of 2018. Cash used in operations during the fourth quarter of 2019 was $15.7 million compared to $12.8 million for the fourth quarter of 2018.

Research and development expenses were $71.0 million for the year ended December 31, 2019 compared to $58.9 million for the year ended December 31, 2018. The increase of $12.1 million was primarily due to a net increase of $2.3 million for personnel-related expenses, which was partially offset by a decrease of $1.1 million related to non-cash stock compensation expense,$6.7 million for outside research and development activities and $3.1 million in lab and facilities-related costs. Research and development expenses were $18.2 million for the three months ended December 31, 2019 compared to $16.3 million for the three months ended December 31, 2018. The increaseof $1.9 million was primarily due to $0.5 million for personnel-related expenses and $1.1 million for outside research and development activities.

General and administrative expenses were $20.0 million for the year ended December 31, 2019 compared to $16.0 million for the year ended December 31, 2018. The increase of $4.0 million was primarily due to an increase of $3.4 million for personnel-related expenses, of which $2.5 millionwas related to non-cash stock compensation expense,and $0.6 million in insurance-related expenses, partially offset by $0.5 million decrease in professional fees. General and administrative expenses were $4.9 million for the three months ended December 31, 2019 compared to $4.3 million for the three months ended December 31, 2018.The $0.6 million increase was primarily due to personnel-related costs, primarily attributable to non-cash stock-based compensation expense.

About UNITYUNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases.More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Forward-Looking StatementsThis press release contains forward-looking statements including statements related to the potential for UNITY to develop therapeutics to extend healthspan. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITYs most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed with the Securities and Exchange Commission on November 6, 2019, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Investors Endurance AdvisorsPeter Rahmerprahmer@enduranceadvisors.com

Media Canale CommunicationsJason Sparkjason@canalecomm.com

Link:
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results - GlobeNewswire

Read More...

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform – BioSpace

Thursday, March 12th, 2020

CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed by Janus Henderson Investors and BlackRock, Rock Springs Capital and a large US-based, healthcare-focused fund. Existing investors also participated in the round.

Kymera also received a strategic investment from The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) directed toward advancing the company's work to treat blood-based cancers.

"We are very excited to be joined by a top-tier group of investors as we continue on our path to become a fully integrated biotech company," said Nello Mainolfi, PhD, co-founder, President and CEO of Kymera Therapeutics. "We are well capitalized to advance up to three programs to the clinic by next year, while we continue to enhance our best-in-class platform to unlock new biology and invent new medicines."

Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics.

Kymera's lead program targets IRAK4, a protein known to play a significant role in inflammation mediated by toll-like and IL-1 receptors. Kymera is planning to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine targeted oncology indications. The company is also developing novel protein degrader therapies to target STAT3, an un-drugged oncogenic transcription factor as well as a driver of inflammation and fibrosis, in a range of cancers and chronic diseases.

"Targeted protein degradation is one of the most promising new therapeutic modalities, with the potential to transform medicine as we know it. Kymera is leading the way with an incredible team, a sophisticated drug discovery platform and important new protein degrader therapies designed to address the most elusive drug targets" said Bruce Booth, DPhil, co-founder, Chairman of the Board of Kymera Therapeutics and partner at Atlas Venture.

About Kymera Therapeutics

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. For more information visit, http://www.kymeratx.com.

About Pegasus

Pegasus is Kymera Therapeutics' proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.

About The Leukemia & Lymphoma Society and Therapy Acceleration Program (TAP)

The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against cancer. The LLS mission: cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS TAP is a strategic initiative that builds business alliances and collaborations with biotechnology companies and academic researchers to identify potential breakthrough therapies with the potential to change the standard of care. LLS TAP funds late stage pre-clinical studies, and proof of concept or registrational clinical trials to help advance these more quickly along the drug development and approval pathway. To learn more, visit http://www.LLS.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/kymera-therapeutics-announces-102-million-series-c-financing-to-advance-its-protein-degrader-pipeline-and-platform-301021994.html

SOURCE Kymera Therapeutics Inc.

Excerpt from:
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform - BioSpace

Read More...

SpaceX is carrying these biotechnology experiments to the ISS this weekend – Digital Trends

Monday, March 9th, 2020

A SpaceX Dragon cargo spacecraft, currently on its way to the International Space Station (ISS) as part of the CRS-20 mission, is carrying a variety of scientific research projects as well as usual food and other supplies for the astronauts. The hardware going to the ISS this weekend includes a number of research projects in biotechnology that could improve the lives of patients here on Earth.

The payloads launching on SpaceX CRS-20 demonstrate that the ISS is not only an amazing multi-purpose, multi-user research facility in low Earth orbit but also a proof-of-concept incubator where industries can advance their applied research and technology development programs, ISS National Lab Chief Operating Officer Ken Shields said in a statement.

Moreover, the diversity of investigations supported by the private sector, government agencies, and academic institutions demonstrates the continued rising demand and interest in utilizing our orbiting laboratory to benefit life on Earth and build a thriving market economy in space.

One experiment by the startup Dover Lifesciences is an attempt to develop protein-based drugs to treat metabolic disorders and obesity. Proteins in the human body play a central role in health and disease and they can also be used as biological agents to treat disease, the ISS National Lab explained in a blog post.

By using protein crystallization to understand the structure of proteins alone and in complex with other molecules, scientists can better design therapeutics to prevent and treat disease. In microgravity, protein crystals can grow larger and with fewer imperfections than on Earth, revealing more detailed protein structures.

The research is looking for drugs that could inhibit the conversion of glucose to glycogen in the liver and muscles. If this were possible, it could be used as a treatment for obesity and some rare genetic disorders, and could even have applications in the treatment of cancer.

Other research includes the development of a small drug pump, shaped like a patch, which can deliver medicine in a controlled and continuous way. For people who have conditions that require regular injections, such as diabetes, this patch could offer an easier and safer way to get the medicine they need regularly.

Finally, the company 1Drop Diagnostics is aiming to develop a portable diagnostic device that can make diagnoses based on very small amounts of blood, which would be invaluable to patients and doctors in remote locations who have limited access to lab equipment.

The Dragon cargo spacecraft is set to arrive at the International Space Station at 4 a.m. PT on Monday, March 9.

Go here to read the rest:
SpaceX is carrying these biotechnology experiments to the ISS this weekend - Digital Trends

Read More...

The Aussie Biotech Companies Trying To Make A Buck From Coronavirus – D’Marge

Monday, March 9th, 2020

This story originally appeared onStockhead.

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the c word. Were talking of course about the coronavirus COVID-19 but sadly not another c word: cure.

Or not yet.

According to broker Morgans daily tally, the virulent bug has so far infected 95,332 people, with 38,564 current cases (6,883 of them critical).

Of the remaining 56,768 cases with an outcome, 53,483 recovered and 6,883 achieved a definitive performance indicator. They died.

Okay, a circa 7 per cent mortality rate or even a 1 or 2 per cent rate is nothing to sneeze at, so to speak. But we do wish breathless TV reporters would cease referring to it as the deadly virus, but that would be like asking them to stop referring to a horror smash rather than a sad everyday road accident.

While were on it, we also implore folk to stop hoarding toilet paper: after all, its the coronavirus, not the Caroma-virus.

Named after its crown-like shape but not the Royal Family per se, the common coronavirus is responsible for past pestilences including Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).

The virus may indeed fizzle out, as the earlier SARS plague did.

But for the time being, we need the best and brightest minds in the labs to come up with a treatment or more likely a vaccine.

There are some promising developments overseas, which your columnist will return to if he hasnt succumbed as well (he did shake hands with someone who went to a Chinese restaurant a couple of weeks back).

Among the local biotechs and we use the term loosely theres been no lack of endeavour in linking their efforts to the virus.

But to be fair, in some cases investors did it for them.

Take Biotron (ASX:BIT), which was an obvious subject of attention given the company is focused on developing antiviral drugs for HIV and hepatitis.

Biotron also has a program for pan respiratory viruses and mentioned corona in a June 2019 presentation. Some punters latched on to the fact that it wasnt referring to a 1970s Toyota or Mexican beer and the Hot Copper pundits were off and running.

Biotron CEO Dr Michelle Miller has been more circumspect.

Yes, she says, the company has some good advanced compounds to work on, but the reality is that theres nothing that would be ready to fight the current outbreak.

Dr Miller says while the companys work on pan respiratory viruses continues, theres not much to add at this stage.

Uscom (ASX:UCM) shares went on a run after the company reported increased orders for its haemodynamic monitoring devices in China.

Uscom stands for Ultra-Sonic Cardiac Output Monitors.

The Uscom 1A device is a non-invasive diagnostic that monitors cardiovascular functions, using Doppler ultrasound to detect abnormalities.

Chinese health authorities have recommended Uscom 1A as a monitoring device for severe coronavirus cases, while international guidelines also suggest using the device for paediatric sepsis.

Uscom reported that in the first five weeks of 2019, Chinese sales orders rose 124 per cent, from 17 units to 38 units.

Uscom chief Professor Rob Phillips says the company is well positioned with the virus, but notes that Uscom is not a coronavirus story as such: fatalities from cardiovascular pulmonary failure result from conditions such as pneumonia.

Happily for Uscom, the outbreak comes as the company hones-in on the Chinese market with a new direct sales model.

The molecular diagnostics house has a suite of approved tests that cover gastro-enteric strains, flavivirus/alphavirus, sexually-transmitted diseases and drum roll respiratory pathogens.

Genetic Signatures (ASX:GSS) Easyscreen tests cover pan coronaviruses, which until now has not been able to distinguish COVID-19 from, say, SARS.

But thats all changed, with the company introducing a supplementary test that does just that. Management is fast-tracking a validation program to obtain the data required for international regulatory approvals as rapidly as possible.

However, Genetic Signatures cant be accused of beating up its prospects: management says while the bug presents significant opportunities, the outcome of the emerging pandemic is uncertain.

While the early-stage coronavirus is detected by a blood test, chest x-rays are then used to gauge the severity of the illness and assess fluid in the lungs.

Micro-X (ASX:MX1) is all about developing lightweight and portable x-ray machines for medical applications, as well as other purposes such as defence and airports.

The companys first product, Carestream DRX Revolution Nano is approved in the US and Europe.

In mid-February the company said it had procured orders for $780,000 of machines from governments of two Asian countries, in response to the coronavirus threat. This week, another $1m of orders, all marked for urgent delivery, flooded in.

While these are terrible circumstances with the coronavirus spreading so quickly, we are pleased that our equipment will soon be able to assist medical teams with their responses in affected countries, Micro-X CEO Peter Rowland says.

Why waste a crisis? No fewer than four ASX stocks are capitalising on demand for hand and surface sanitisers to halt the bug in the first place.

Antimicrobial solutions house Zoono Group (ASX:ZNO) proclaims that its impressively-monikered Z-71 Microbe Shield, as used in its hand sanitisers, kills COVID-19 99.99 percent of the time.

Zoono is selling into China via a tie up with Eagle Health (ASX:EHH), which manufactures and distributes product into 26 provinces.

Aeris Environmental (ASX:AEI) goes one step better, claiming its Aeris Active product kills influenza and noroviruses in 99.999 percent of cases.

For those remaining 0.001 percent, bad luck and dont buy a lottery ticket.

Interestingly, that announcement did not refer specifically to the coronavirus. But earlier, Aeris announced the Singapore National Environment Agency had listed Aeris Active as one of the general disinfectants effective against the virus.

Meanwhile, fruit juice maker Food Revolution Group (ASX:FOD) has turned from filling its bottles with squeezed oranges to stuffing them with alcohol-based hand sanitiser under the Sanicare brand.

Who would have thought? The swift repositioning results from a 1,260sqm upgrade at the companys plant at Mill Park in outer Melbourne, which enables all sorts of gels, powders, oils and cosmetics to be bottled.

Mainstream sanitiser products such as Dettol and Lysol (made by multinational Reckitt and Benckiser) are flying off the shelves.

But is a good scrub with soap and water just as effective? Australian National University microbiologist Professor Peter Collignon opines theres little difference between hand washing and the alcohol-based sanitisers.

One is just more convenient than the other and contains alcohol, he says. You can put it in your pocket and dont have to be near a sink or basin to use it.

So whos actually tackling the disease? Offshore, theres a conga line of developers having a crack at a vaccine.

In Israel, scientists at the Galilee Research Institute claim to be on the cusp of finalising a product that is capable of getting regulatory assent within 90 days.

Thats what you call fast-track approval.

According to the Jerusalem Post, the same team of scientists has been developing a prophylactic against infectious bronchitis virus, which affects poultry.

The effectiveness of the vaccine has been proven in pre-clinical trials carried out at the countrys Veterinary Institute.

In the US, Gilead Sciences plans to recruit 1,000 patients with coronavirus for a clinical trial to test its experimental anti-viral drug remdesivir (as used to tackle Ebola virus).

With the backing of the World Health Organisation, the drug is also being trialed in China.

Maryland-based, Nasdaq-listed Novavax says it is cloning the coronavirus to develop a vaccine, in the same way it developed one for MERS in 2013.

Novavax is looking at several vaccine candidates for animals and hopes to find one for human testing by the end of May.

Our previous experience working with other coronaviruses, including both MERS and SARS, allowed us to mobilise quickly, Novavax CEO Stanley Eck said.

Fellow Nasdaq minnow Moderna has shipped an experimental vaccine to the National Institute of Allergy and Infectious Diseases for testing.

Backed by billionaire hedge fund founder Jim Simons, Long Island-based private outfit Codagenix expects to have a vaccine ready for animal testing in four to six weeks, with one suitable for testing about six weeks later.

The Codagenix know-how is based on recoding the genomes of viruses to render them harmless. The technique is not exactly unknown, as its been used to eradicate polio and small pox.

And who can forget Australias very own Relenza anti-influenza Biota, which became Alpharetta Georgias Nabi, changed its name to Aviragen and then was subsumed as a sub-division of San Franciscos Vaxart, popping its head above the parapet to also claim an anti-viral program for COVID-19.

The South China Morning Post reports that a 65-year-old woman on her COVID-19 deathbed walked out of Chinas Kunming Hospital after being given a stiff shot of mesenchymal stem cells (MSCs).

Two trials are also underway to test the therapy against pneumonia, at a Beijing Military Hospital and Zhongnan Hospital of Wuhan University (yep, in the coronavirus capital).

Could the excitement rub-off on our ASX-listed plays Mesoblast (ASX:MSB), Cynata Therapeutics (ASX:CYP), Orthocell (ASX:OCC) and Regeneus (ASX:RGS)?

Cynatas Dr Ross Macdonald says the reports look authentic; and he believes that MSCs could be an effective adjunct in managing patients with serious issues pertaining to COVID-19.

This is not because MSCs are inherently anti-viral or can act as a vaccine, but more because they have shown benefit in major pathologies associated with infection, he says.

Cynata, we stress, has not mentioned coronavirus in its dispatches and nor has any of the other non-China MSC plays or not yet anyway.

But still, what decent CEO would not give his company a plug?

The clear advantage of (Cynatas) Cymerus technology (is) the ability to make large quantities of consistent, robust MSCs without having to find gazillions of donors, Dr Macdonald says.

Your columnist stresses that the coronavirus influence on the sector is not all positive, with some biotechs likely to be affected by supply or other disruptions.

In mid-February, Cochlear (ASX:COH) quickly stepped off the mark by announcing its earnings for the 2019-20 year were likely to come in at $270-290m, compared with the previously guided $290-300m.

The reason is that hospitals in China and Hong Kong have delayed cochlear implant procedures to avoid the risk of infection.

The aforementioned Uscom notes that with labs preoccupied with the virus, short-term revenues are less predictable. In other words, the coronavirus is a distraction as well as an opportunity.

IDT Australias (ASX:IDT) Dr David Sparling told Biotech Daily that his company had no direct supply chain exposure to China at all, and was doubtful that even the companys gowns and protective gear had much to do with the Middle Kingdom.

Editors note: Dr. Tim Boreham, who wrote this article for Stockhead, is one of Australias best-known small cap analysts and business journalists.

If you throw enough money and resources at tackling a disease you will get a result, right?

Er, not quite: cures for well-researched ailments such as Alzheimers disease, multiple sclerosis and an array of cancers remain elusive.

But when youve got an ailment that is crippling the global economy, the imperative to find a solution is somewhat more intensive.

Our best guess is that like SARS and MERS, COVID-19 will hang around for years to come, but the ill-effects will be made more tolerable with an effective vaccine and/or improved immunity over time.

In other words, it will become just another disease in the pantheon of maladies blighting humanity.

In the race for a cure, Gileads Remdesivir looks interesting, given it has been used before.

As for the opportunists in the sanitiser game, the surge in demand means tangible revenue gains and good on them.

But lets be clear: theyre hardly breaking new ground technology-wise and their gains will only be short term as other suppliers enter the market.

As for a cure, or lack of one, we suggest that investors hedge their bets with an exposure to the funeral stocks Invocare (ASX:IVC) and Propel Funeral Partners (ASX:PFP).

After all, theyre the last people to let you down.

Stockheadcovers emerging ASX companies and investment opportunities. Get daily stock updates atStockhead.

See the original post here:
The Aussie Biotech Companies Trying To Make A Buck From Coronavirus - D'Marge

Read More...

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Size, Shares, Key Players, Demand, Supply, Growth and Forecast to 2026 – 3rd Watch News

Monday, March 9th, 2020

New Jersey, United States,-The Nanoparticles in Biotechnology and Pharmaceuticals Market report was created with experience and knowledge by market analysts and researchers. It is a phenomenal compilation of important studies that examine the competitive landscape, segmentation, geographic expansion and sales growth, production and consumption of the Nanoparticles in Biotechnology and Pharmaceuticals market. Players can use the reports accurate market data and numbers, as well as statistical studies, to understand the current and future growth of the Nanoparticles in Biotechnology and Pharmaceuticals market. The report includes CAGR, market share, sales, gross margin, value, volume and other key market numbers that provide a clear picture of the growth of the Nanoparticles in Biotechnology and Pharmaceuticals market.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=3WN&utm_medium=001

Top Key Players of the Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

Our analysts have used advanced primary and secondary research techniques and tools to prepare this report. The sources and research tools we use are extremely reliable. New players can also use this research study to develop business strategies and learn about future market challenges. We offer a complete competitive analysis that includes a detailed company profile of the main players, a study of the nature and characteristics of the supplier landscape and other important studies.

Leading Regions

The research study contains important results and insights from our monitoring and analysis of the market for Nanoparticles in Biotechnology and Pharmaceuticals industry. We have provided key data points, including divestments, launches, enhancements, partnerships, mergers, acquisitions, and other strategic initiatives by players in the Nanoparticles in Biotechnology and Pharmaceuticals market. The report also includes price developments for regional markets and an analysis of important market events at regional and global levels. Our analysis enables you to make informed decisions in the market for Nanoparticles in Biotechnology and Pharmaceuticals in terms of acquisitions, inventory, prices and production. We enable you to offer your opponents tough competition by providing fast, actionable market information in real time.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=3WN&utm_medium=001

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Customized Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=3WN&utm_medium=001

Highlights of the Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market

Our Trending Reports

IT Training Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Size, Shares, Key Players, Demand, Supply, Growth and Forecast to 2026 - 3rd Watch News

Read More...

With $15M Series A, Culture Biosciences Is Growing Cells In The Cloud – SynBioBeta

Monday, March 9th, 2020

As someone immersed in the biotechnology sector, Ive seen my share of startup stumbles. Giddy teams of brilliant scientists promising the next generation ofthisor sustainablethatoften fail to deliver, not because their core ideas are faulty but because they so often fail to get their arms around the true complexity of manufacturing.

Having a great idea for how biotechnology might improve lives is one thing think compostable plastics or alternative meats. But bringing those bold visions into reality is quite another.

Thats whereCulture Biosciencescomes in. Based in South San Francisco, the company has been stocking up on the type of expensive laboratory equipment bioreactors that most other biotechnology firms pour millions of dollars into. Culture then rents its physical lab equipment out to paying customers via an online portal. Think AWS, but for biology.

In this way, Culture is aiming to permanently reduce the complexity of biomanufacturing, allowing its customers to skip expensive investments in equipment and bring their goods to market sooner.

Culture today announced that it plans to triple its bioreactor capacity thanks to a new $15 million Series A, led byCultivian Sandbox Ventureswith participation fromThe Production Boardand existing investors. For full disclosure, Im also an investor in this company through my role as an Operating Partner atDCVC.

Bioreactors are used to grow cells, which in turn can grow almost anything. Recent breakthroughs in synthetic biology now mean that scientists can program living cells more precisely than ever. Synthetic biology and biofabrication hold the answers to so many of the challenges we face today, says Will Patrick, Cultures co-founder and CEO.

We spent time talking to scientists working in industrial biotechnology, learning about their work in detail. There were so many companies working on potentially game-changing products, ranging from alternative food proteins to bio-based chemicals to life-saving medicines. Yet, they all faced formidable challenges in taking their lab-scale discoveries and turning them into commercially viable products at scale. We heard time and time again that the process of scaling-up from the bench to production was time-consuming, risky, and expensive. There were also so many stories about potentially promising products failing to be scaled-up to production successfully.

Culture already services some notable customers, includingZymergen, which is breeding microbes that produce value-added molecules for a number of industries, andClara Foods, which is working to fast-track new sources of animal-free protein. Other new customers includeNektar Therapeutics,C16 Biosciences, andBoost Biomes.

Its a business model built on trust. As Culture expands, its stockpile of bioreactors which could soon exceed 300 must keep up with customers demands. By offering a reliable cloud service that can quickly be scaled up or down according to need, Culture hopes to save its customers lots of money in the long run.

Our mission is to build an end-to-end platform where bioprocess scientists can manage their entire workflow in our software application, said Patrick. In our conversations with scientists, we identified the bench-scale bioreactor lab as a key bottleneck in the scale-up process. Running bench-scale bioreactors to screen strains and develop bioprocesses is critical for developing new products, but it is also time-consuming, labor-intensive, and expensive.

At the moment, Patrick tells me that his customer base is roughly 60 percent biopharma and 40 percent industrial biotechnology. But I think it will flip. Im really big on the industrial biology sector. These spaces are massive, and the opportunity is so huge.

Platforms that broadly enable scientists, engineers, and innovators to do more for less could add fuel to the already hot synthetic biology sector. I recently wrote about howinnovations in bio-nylon could soon unlock a $10 billion sector, how investments into synthetic biology made here on Earth couldaid in 21st-century efforts to explore and inhabit space, and how synthetic biology companies arenow racing to stop coronavirus.

Disruptors like Culture Biosciences renew my hope that this biological revolution is here to stay.

Follow me on twitter at@johncumbersand@synbiobeta. Subscribe to my weekly newsletters insynthetic biologyandspace settlement.

Thank you toIan Haydonfor additional research and reporting in this article. Im the founder ofSynBioBeta, and some of the companies that I write aboutincludingCulture Biosciencesare sponsors of theSynBioBeta conferenceandweekly digestheres the full list of SynBioBeta sponsors. Im an operating partner atDCVC, which is an investor in Culture Bioscience.

Originally published on Forbes https://www.forbes.com/sites/johncumbers/2020/03/04/with-15m-series-a-culture-biosciences-is-growing-cells-in-the-cloud/

Read more here:
With $15M Series A, Culture Biosciences Is Growing Cells In The Cloud - SynBioBeta

Read More...

University of Minnesota Twin Cities senior awarded a Churchill Scholarship to study at the University of Cambridge – UMN News

Monday, March 9th, 2020

Macy Vollbrecht, a senior majoring in genetics, cell biology and development in the College of Biological Sciences at the University of Minnesota Twin Cities, has been named a Churchill Scholar by the Winston Churchill Foundation of the United States.

The scholarship, worth approximately 60,000 USD, will allow Vollbrecht to spend the 2020-21 academic year at Churchill College of the University of Cambridge. There, she plans to complete a masters of philosophy in plant sciences with an emphasis on plant development. Her research, conducted with Sainsbury Laboratory Director Prof. Ottoline Leyser, will focus on plant plasticity. Particularly, how alterations in cytokinin homeostasis and cytokinin-mediated regulation of hormones affect shoot branching in plants.

The daughter of Erik Vollbrecht and Susan Barry of Ames, Iowa, Vollbrecht began research in genetics with Prof. Maura McGrail at Iowa State University in a National Sciences Foundation program for young scientists and engineers in 2015. She was invited to continue that research the following summer, before she enrolled at the University of Minnesota Twin Cities.

At the U of M, she began working in Prof. Daniel Voytas lab in her freshman year. The Voytas Lab has been developing an innovative method to accelerate gene editing in plants using an expression of developmental regulator genes. At the Voytas Lab, Vollbrecht had the opportunity to design and carry out experiments that have been published in Nature Biotechnology.

In addition to her work at the U of M, Vollbrecht:

Volbrecht has been recognized by her department, the College of Biological Sciences and the larger-University with scholarships awarded to top students. These include: the Franklin Enfield Memorial Scholarship; Monica Tsang and James Weatherbee Scholarship; and the Genetics, Cell Biology and Development Scholarship. In addition, she was one of 52 students nationally to be awarded an Astronaut Scholarship in 2019.

The Churchill Scholarship is awarded to fifteen seniors majoring in the sciences, engineering and mathematics at colleges and universities across the United States, making it one of the most selective and prestigious postgraduate scholarships. Vollbrecht is the fifth U of M student in six years to be awarded a Churchill scholarship, following Max Shinn, math and neuroscience; Sammy Shaker, chemistry; Anthony Tabet, chemical engineering; and Merrick Pierson Smela, chemistry and biochemistry.

###

The Winston Churchill Foundation of the United States was founded in 1959 to offer U.S. students of exceptional ability and achievement in the sciences, engineering and mathematics the opportunity to pursue graduate studies at the University of Cambridge. Nine graduates of the University of Minnesota have previously been named Churchill Scholars. Students at the University of Minnesota who are interested in the Churchill Scholarship or other major competitive awards to fund graduate or undergraduate study, in the United States or abroad, should contact Timothy Jones in the Office of National and International Scholarships at natschol@umn.edu.

View original post here:
University of Minnesota Twin Cities senior awarded a Churchill Scholarship to study at the University of Cambridge - UMN News

Read More...

Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for US Air Force Needs – BioSpace

Monday, March 9th, 2020

NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation(NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Air Force (USAF) has awarded Daxor a contract to define specifications to adapt blood volume analysis technology to meet the needs of USAF.

The selection was made under the USAFs Small Business Innovative Research (SBIR) program. The contract award will be to validate the product-market fit between Daxors blood volume analyzer and USAF stakeholders and define technological enhancements desirable to facilitate adoption of the device by USAF and other defense stakeholders.

Daxor looks forward to adapting its technology to provide time sensitive, mission critical care information and decision support to the specially trained personnel within the Air Force, said Michael Feldschuh, CEO of Daxor Corporation.

"This opportunity enables us to continue to push our research and development program forward, opening new applications for our technology says Jonathan Feldschuh, Chief Scientific Officer. We are focused on making blood volume measurement simpler and quicker to perform, whether in an aircraft, a field hospital, or at the patient bedside.

This is the second award for Daxor with the Department of Defense (DoD). SBIR contracts are designed to stimulate innovation by companies to develop technologies and solutions that meet critical Army needs. SBIR programs benefit the DoD and the private sector and support the nations economic growth.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information please visit our website at https://www.daxor.com

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact

Bret ShapiroSr. Managing Partner, CORE IR516-222 -2560brets@coreir.com

Go here to see the original:
Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for US Air Force Needs - BioSpace

Read More...

Turkey eager to invest in biotech – Anadolu Agency

Monday, March 9th, 2020

ANKARA

Turkey's progress in the health sector is strategically critical beyond its economic significance, the Turkish president said on Saturday.

Congratulating the award recipients of the international biotechnology congress BIO Turkey in Istanbul, Recep Tayyip Erdogan in a letter stressed the importance of the pharmaceutical industry for Turkey

Erdogan underlined that the sector was the most important after the defense industry, emphasizing that during difficult times Turkey could only rely on its own production and infrastructure to survive.

"However, we have unfortunately faced veiled resistance in our steps to develop our domestic and national pharmaceutical industry and strengthen our medical device sector, just as we once had in the defense industry," he said.

Attending the ceremony, Vice President Fuat Oktay said that Turkey would act against "approaches" that sought to compel domestic ventures to move abroad even as the government attempted to bring research and development, design and production facilities into the country.

Inviting scientists, non-governmental organizations and universities to support Turkey's biotechnology initiatives, Oktay said investments in the defense, health and food industries would "not only save us from dependency but also turn Turkey into a global exporter."

Health Minister Fahrettin Koca also spoke at the ceremony, underscoring the role of partnerships between academia, industry and individual projects in training a qualified labor force.

After his speech, Koca presented a plaque of appreciation to the representatives of the congress's sponsors.

*Writing by Davut Demircan

See more here:
Turkey eager to invest in biotech - Anadolu Agency

Read More...

Worldwide Wound Care Market Summary 2017-2024 – Focus on Biotechnology: Advanced Biodressings, Negative Pressure Wound Systems, and More -…

Friday, March 6th, 2020

Dublin, March 05, 2020 (GLOBE NEWSWIRE) -- The "Worldwide Wound Care Market Summary" report has been added to ResearchAndMarkets.com's offering.

Wound care is very much a challenge for both patients and healthcare providers.

Worldwide Wound Care Market Summary identifies a market opportunity for major sectors of this important market. A particular focus is given to biotechnology used in wound care, including advanced biodressings and negative pressure wound systems.

Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth in the market during the report's forecast period. Growth is also being driven by the introduction of portable, single-use products in negative pressure wound therapy.

The report focuses on wound care advancements, providing a table of newly approved wound care products for 2019. The aging of the population and continued advances in biotechnology drive the wound care industry. It is the goal of new and existing product manufacturers to offer products designed to improve healing rates and prevent wound formation.

Market data in the report include:

World Market

Total Market by Segment

Market Segments by Application

Market by Application

The report also contains current market size for the total wound care products market for the following countries and regions:

Worldwide Wound Care Market Summary provides an outline of the competitive market, including the following data points:

Industry participants have attempted to diversify their offerings by acquiring smaller companies with new and innovative technology. This move has created more competition among large wound care companies.

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: Total Worldwide Wound Care Market Size, Forecast, and Competitive Analysis

Chapter 3: Wound Care Advancements

Chapter 4: Top Five Company Profiles(Company Overview, Performance Review)

A-Z List of Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/eyoxce

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Visit link:
Worldwide Wound Care Market Summary 2017-2024 - Focus on Biotechnology: Advanced Biodressings, Negative Pressure Wound Systems, and More -...

Read More...

Vir Biotechnology and Alnylam Join the Fight Against COVID-19 – Motley Fool

Friday, March 6th, 2020

Yet another biotech has joined the fray against the novel coronavirus: Alnylam Pharmaceuticals (NASDAQ:ALNY) andVir Biotechnology (NASDAQ:VIR) on Wednesday announced they were expanding their ongoing collaboration to include an attempt to develop RNA interference (RNAi) treatments for SARS-CoV-2.

According to the American Society for Microbiology, coronaviruses are everywhere. They are the second-leading cause of the common cold, after rhinoviruses. In an article on the society's website, Dr. Rodney Rhode wrote, "Coronaviruses ... mutate and change at a high rate, which can create havoc for both diagnostic detection as well as therapy (and vaccine) regimens."

Image source: Getty Images

The two companies have been collaborating since the 2017 founding of Vir, which specializes in using immunology to fight and prevent infectious diseases. Vir CEO George Scangos was the CEO ofBiogenbefore he took control of the start-up.

"Given the scope and speed of the COVID-19 outbreak," Scangos said, "Vir is seeking multiple approaches that combine our expertise in infectious disease with that of current and new partners to respond rapidly. Alnylam has been an excellent partner, and our complementary capabilities made this a compelling opportunity..."

As Alnylam CEO John Maraganore said, "We believe RNAi therapeutics represent a promising approach for targeting coronaviruses, like SARS-CoV-2. As the leader in RNAi therapeutics, we at Alnylam are committed to doing our part in joining other biopharmaceutical companies, like Vir, to address this emerging outbreak."

Vir will lead all development and commercialization of any selected drug molecules. Alnylam retains the option to share in the profits and losses associated with the effort. Shares of Vir were up 14% in early trading Wednesday, while Alnylam was up 3%.

{%sfr%)

Read more from the original source:
Vir Biotechnology and Alnylam Join the Fight Against COVID-19 - Motley Fool

Read More...

Vir Biotechnology: Avoid This Overvalued Stock In March 2020 – Seeking Alpha

Friday, March 6th, 2020

The decision to buy or sell a stock is dependent not only on the company fundamentals but also on its trading price. Many strong businesses enter the avoid or sell zone, simply because of exaggerated prices and seemingly little to no upside potential. One such stock that a value investor needs to shy from is Vir Biotechnology (VIR).

Today, we will see why fundamentals fail to justify Vir Biotechnology's valuation levels.

Vir Biotechnology is a clinical-stage immunology company focused on developing novel treatments targeting infectious diseases. The company's four therapeutic platforms, antibody platform, T Cell platform, Innate immunity platform, and siRNA platform, are working on enhancing the immune response to pathogens. The company's lead asset, VIR-2218, is currently being evaluated in Phase 2 in HBV (hepatitis B) indication. Besides, the company also has multiple early-stage investigational drug candidates being evaluated in tuberculosis, influenza, and HIV indications.

Recently, though, the stock has jumped over 100% on news of its involvement in researching antibodies that can work against the novel coronavirus or COVID-19 virus strain.

On February 12, Vir Biotechnology announced that it has identified two monoclonal antibodies that bind to the SARS-CoV-2 virus which causes the COVID-19 disease. These antibodies are targeting the SARS-CoV-2 spike protein in the region that the virus uses to enter cells through the cellular receptor ACE2. On February 25, the company announced a manufacturing collaboration with WuXi Biologics to advance and produce human monoclonal antibodies for the potential treatment of COVID-19.

Although these are promising developments especially in a world fighting a pandemic, the fact remains that the company is not even close to commencing first-in-human trials for the investigational COVID-19 therapeutic. The company has isolated antibodies from patients who survived SARS and is studying it for COVID-19 in the preclinical stage. The company may require around 10 months, provided everything goes without a glitch, to get the first human dosed with this therapy.

Gilead Sciences (GILD) seems to be much ahead in the quest of COVID-19 therapy. On February 26, the company announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19. In these randomized, open-label, multicenter studies, the company plans to enroll 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March to evaluate two dosing durations of remdesivir, administered intravenously. FDA has already reviewed and accepted the company's IND (investigational new drug) filing for remdesivir for the treatment of COVID-19. This follows the article published in The NEJM (New England Journal of Medicine) which highlighted clinical benefit witnessed by a COVID-19 patient in the U.S. on the administration of remdesivir.

Remdesivir is already being studied in two clinical trials, in China's Hubei province led by the China-Japan Friendship Hospital as well as the recently initiated clinical trial in the United States led by the National Institute of Allergy and Infectious Diseases.

Then, there is Regeneron (REGN), also working on an antibody approach to finding a cure for COVID-19. The company's technology platform demonstrated robust outcomes in the Ebola outbreak of 2015.

There is also much activity in the vaccine space for COVID-19. We also have Moderna Therapeutics (MRNA) working with the NIH (National Institutes of Health) to evaluate mRNA-1273 as a vaccine candidate for COVID-19 in the Phase 1 trial. The company will be studying the vaccine candidate in the healthy-volunteer study expected to begin in April. If proven safe, Moderna and NIH plan to enroll hundreds of more patients to determine whether the vaccine protects against infection. We also see other companies such as Sanofi (SNY), Inovio Pharmaceuticals (INO), CureVac, and GlaxoSmithKline (NYSE:GSK), analyzing various vaccine candidates in the preclinical stage.

Vir Biotechnology is definitely not a forerunner in this race for COVID-19 treatment. Hence, the investor exuberance and the more than 100% jump in share prices since February 24 does not seem justified by company fundamentals.

Vir Biotechnology and Alnylam Pharmaceuticals (ALNY) are working on investigational subcutaneously administered HBV-targeting siRNA (Small interfering RNA), VIR-2218, in Phase 1/2 clinical trial. This drug is designed to inhibit the production of all HBV proteins including HBsAg (HBV surface antigen). HBsAg is developed by the HBV virus to inhibit T-cell activity against the infection.

In January 2020, Vir Biotechnology announced new pipeline data from the ongoing Phase 2 trial of VIR-2218. The data demonstrated substantial reductions in HBsAg and also high tolerability of the therapy. All HBeAg negative and positive patients who received two doses of 200 mg of VIR-2218 reported at least a 1.0 log10 decline in HBsAg as well as a mean decline of 1.5 log10 in HBsAg at day 85.

Further, none of the patients demonstrated ALT (alanine amino transaminase) greater than or equal to three times the upper limit of normal, validating the manageable tolerability profile of the therapy.

Vir Biotechnology expects 16-week data across all cohorts in the first half of 2020. The company also plans to commence two new trials with VIR-2218 by late 2020. These include a Phase 2 trial in China in collaboration with Brii Biosciences, and another Phase 2 combination trial of VIR-2218 and pegylated interferon-alpha (PEG-IFN-). The company is also working on advancing CTA (clinical trial application) for the investigational HBV vaccine, VIR-3434, in the first half of 2020.

Although there are impending milestones and catalysts for Vir Biotechnology in 2020, none of them justify the company's current valuation multiples. Currently, Vir Biotechnology is trading at a price-to-sales multiple of 626.43x and price-to-cash flow multiple of 19.95x.

Other hepatitis B players such as Ionis Pharmaceuticals (IONS), GlaxoSmithKline, Arrowhead Pharmaceuticals (ARWR), and Arbutus Biopharma are trading at much lower price-to-sales multiples of 6.88x, 2.55x, 22.46x, and 30.80x, respectively.

Besides the valuations, there are many other risks associated with this company. Vir Biotechnology is a clinical-stage company and can continue to report losses for many more years. Infectious disease players have historically got the short end of the stick in terms of biopharmaceutical funding. Unlike chronic lifestyle conditions, there may come a stage when a majority of infectious disease patients are cured. We have seen this for the Gilead Sciences Hepatitis C franchise. There remains a high possibility that after the initial bolus of patients, hepatitis B players may also face a rapid decline in the addressable market and extraordinary profits.

The company is also in the early stage of clinical development and faces significant R&D failure risk. It does not have a history of advancing molecules in the late-stage of clinical development or of securing regulatory approvals. The company also does not have experience of successfully commercializing products. This exposes the company to a significant degree of market uncertainty.

One upside for the company, however, is its stable cash balance of around $320 million at the end of September 2019. Assuming that the company's cash burn rate is similar to the cash spent on operational activities of around $120 million in 12 months ending September 2019, the company may not need dilutive financing at least till the end of 2021. However, the company may still choose to go for equity dilution to take advantage of its stratospheric valuations.

According to finviz, the 12-month consensus target price for the stock is $26.33. On February 27, Baird analyst Madhu Kumar downgraded Vir Biotechnology to Underperform from Neutral and reiterated the target price of $17. On February 4, JPMorgan analyst Anupam Rama downgraded Vir Biotechnology to Neutral from Overweight but raised the price target from $25 to $26.

In November 2019, Goldman Sachs analyst Paul Choi initiated coverage with a Buy rating and $37 price target. Barclays analyst Gena Wang initiated coverage with an Overweight rating and $25 price target.

Here again, we see that the modest fiscal 2020 revenue and EPS estimates do not support Vir's high valuations.

In this backdrop, I believe that a target price range of $25 to $28 is a fair estimate of the true growth potential of Vir Biotechnology in 2020. This is definitely a promising biotechnology company, but investors should not pick this company at unsustainable valuations. Instead, it is advisable even for aggressive investors to wait for a better entry point to pick this stock in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more:
Vir Biotechnology: Avoid This Overvalued Stock In March 2020 - Seeking Alpha

Read More...

Global Life Science Tools Market to Expand with Advancements in the Field of Biotechnology – BioSpace

Friday, March 6th, 2020

The global life sciences tools market has been growing with advancements in the field of biological research and testing. It is evident that the global life sciences sector has been transforming into a pool for investment and lucrative growth. The changing financial trends pertaining to this sector have given a boost to the growth of the global life sciences tools market. The presence of multiple biological research institutes has given a thrust to the growth of the global life sciences tools market. Moreover, the focus given on improved biotechnologies by medical professionals has also generated stellar demand within the global market.

This blog by Transparency Market Research (TMR) on the global life sciences tools market is a deft explanation of the forces that have aided market growth.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2358

The growing incidence of genetic disorders has played a major role in the growth of the global life sciences tools market. The domain of molecular biology has emerged as a haven of opportunities due to the advent of improved research facilities. The use of life sciences tools such as instruments, reagents, and consumables in the field of biomedicine has given a strong impetus to the growth of the global market.

On the basis of geography, the global life sciences tools market can be segmented into North America, the Middle East and Africa, Europe, Latin America, and Europe. The life sciences tools market in North America is expanding with advancements in the domain of biochemical research.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2358

Geographically, the global life sciences tools market is segmented into Europe, North America, Asia Pacific, and Rest of the World. Of these, North America has led a leading position and is projected to maintain its stance in the coming years. The North America life sciences tools markets position will be attributable to the increasing investments in research and development activities. The strong presence of pharmaceutical companies in the region are also expected to make a significant contribution to the markets rising revenue.

The Asia Pacific life sciences tools market is also show steady progress over the next few years. The emergence of the healthcare sector in the region and the increasing expenditure on treatment of various conditions are expected to propel the market in this region. The improving economic conditions of the developing countries in Asia Pacific are also expected to bode well with the regional market.

Pre Book Life Science Tools Market Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=2358&ltype=S

Key Players Mentioned in the Report are:

The leading players operating in the global life sciences tools market are F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., EMD Millipore (Merck KGaA), Sigma-Aldrich Corporation, and Life Technologies (Thermo Fisher Scientific Corporation).

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Global Life Science Tools Market to Expand with Advancements in the Field of Biotechnology - BioSpace

Read More...

House Okays $8 Billion Funds to Combat COVID-19: 3 Winners – Yahoo Finance

Friday, March 6th, 2020

The House of Representatives passed a bill for allotment of funds in an emergency pool earlier this week, which is to be used to counter the damaging effects of the coronavirus outbreak is expected to have on the domestic economy.

Let us analyze which stocks are expected to benefit from this emergency stash.

House Allocates $8 Billion to Emergency Funds

On Mar 4, the House passeda legislation that allocates more than $8 billion to emergency funds to battle against the spread of coronavirus. The bill won by a voting ratio of 415-2. Republican lawmakers Ken Buck of Colorado and Andy Biggs of Arizona were the only members who voted unfavorably.

The emergency funds aim to provide more than $3 billion for vaccine research and $2.2 billion for efforts in prevention and preparedness. Medical tests and vaccine research to combat the pandemic are urgent tasks right now, which many biotechnology firms in the country are working on actively.

Companies, such as Moderna, Inc. MRNA, Inovio Pharmaceuticals, Inc. INO and Vir Biotechnology, Inc. VIR are currently in the process of developing the much-needed vaccines.

The congressional spending proposal is considerably higher than the $2.5 billion that the White House had proposed in late February. The bill also authorizes about $500 million to allow Medicare providers to offer telehealth services, which would benefit elderly patients to receive care in the comforts of their homes.

The bill is now headed to the Senate for approval. Should it be passed effectively, it will then make its way to President Donald Trumps desk, who is expected to give a green signal. Trump had earlier indicated at a news conference that he would spend whatever is appropriate to fight the COVID-19 outbreak.

After all, death toll in the United States climbed to 11 and minimum 138 are infected. Of the 11, 10 deaths were confirmed from Washington while one was registered in California. Globally, the pandemic claimed more than 3,100 lives.

Story continues

3 Stocks in Focus

We have, therefore, handpicked three vital stocks that are actively developing vaccines to address the novel coronavirus. One may take a closer look at these.

Modernais a clinical stage biotechnology company. Last week, the company saidthat its first batch of vaccine against the COVID-19 disease, called mRNA-1273, was ready for the government to test on humans.

The Zacks Consensus Estimate for Modernas current-year earnings has moved 5% north in the past 60 days. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 40.5% against the industrys decline of 2.6% on a year-to-date basis. (Read more)

Moderna carries a Zacks Rank #2 (Buy). You can seethe complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Inovio Pharmaceuticalson Mar 4 announcedan accelerated timeline to develop its DNA vaccine INO-4800 to battle COVID-19. Inovio's President & CEO Dr. J. Joseph Kim mentioned this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on Mar 2.

Inovio Pharmaceuticals carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 143.2% against the industrys decline of 2.6% on a year-to-date basis.

Vir Biotechnologyis a clinical-stage immunology company. The firm, along with Alnylam Pharmaceuticals, Inc. ALNY, announcedon Mar 4 that the two companies would expand their continuing collaboration to make an attempt to develop RNA interference treatments for SARS-CoV-2.

Vir Biotechnology carries a Zacks Rank #3. Shares of this company, which belongs to the Zacks Medical - Biomedical and Geneticsindustry, have risen 257% against the industrys decline of 2.7% on a year-to-date basis.

Free: Zacks Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the companys drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportModerna, Inc. (MRNA) : Free Stock Analysis ReportAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis ReportInovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis ReportVir Biotechnology, Inc. (VIR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

Read this article:
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners - Yahoo Finance

Read More...

Industry Analysis: Should You Buy Provention Bio Inc (PRVB) in Biotechnology? – InvestorsObserver

Friday, March 6th, 2020

Provention Bio Inc (PRVB) is near the top in its industry group according to InvestorsObserver. PRVB gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Provention Bio Inc gets a 96 rank in the Biotechnology industry. Biotechnology is number 21 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Provention Bio Inc (PRVB) stock is trading at $11.46 as of 2:34 PM on Tuesday, Mar 3, a drop of -$0.78, or -6.37% from the previous closing price of $12.24. The stock has traded between $11.31 and $12.71 so far today. Volume today is less active than usual. So far 305,664 shares have traded compared to average volume of 536,536 shares.

To see InvestorsObserver's Sentiment Score for Provention Bio Inc click here.

Originally posted here:
Industry Analysis: Should You Buy Provention Bio Inc (PRVB) in Biotechnology? - InvestorsObserver

Read More...

German and UK researchers cut time to sepsis diagnosis – European Biotechnology

Friday, March 6th, 2020

Researchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.

In theJournal of Molecular Diagnostics, a research team led by Kai Sohn from Fraunhofer IGB (Stuttgart, Germany) describes the new real-time NGS-based technique that allows an accurate diagnosis of sepsis-causing agents within a few hours of drawing blood. Current diagnostic tests are culture- or PCR-based, which are neither fast nor specific enough to provide timely, critically important information.

"With up to 50 million incident sepsis cases and 11 million sepsis-related deaths per year, sepsis represents a major cause of dealth," explained co-lead-investigator Thorsten Brenner, MD, vice head of the Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany. "Reliable and early identification of the pathogen enables rapid and the most appropriate antibiotic intervention, thereby increasing the chance of better outcomes and patient survival. Currently, standard-of-care diagnostics still rely on microbiological culturing of the respective pathogens, which rarely provide timely positive results."

The investigators described a system that utilized NGS of microbial cell-free DNA to detect blood pathogens within 28 hours. However, their ultimate goal was to develop an even faster test to expedite treatment. To overcome this limitation the investigators established a diagnostic workflow based on 3rd generation nanopore sequencing of microbial DNA. Normally, nanopore sequencing is used to analyze long fragments in sufficient amounts. However, microbial cell-free DNA occurs in small fragments and low quantities in plasma. Nanopore sequencing offers the possibility of real-time analyses during sequencing, which dramatically reduces the time needed to obtain results. "We also had to create validated, specifically adapted bioinformatic procedures to reliably identify pathogens," noted Sohn.

This new technique relies on the use of the handheld nanopore sequencer MinION developed by Oxford Nanopore Technologies. According to the company, the handheld sequencer can read out ultra-long reads, and immediately processes reads in real time.

In their pilot study, the investigators analysed plasma from four septic patients and three healthy controls who were hospitalized in the intensive care unit (ICU). Each sample's DNA underwent sequencing using both technologies: the standard NGS (from world market NGS leader Illumina, which finished a MinION partnership) and the nanopore NGS technology. With nanopore sequencing, all septic patient samples were found to be positive for relevant pathogens, whether bacterial, viral, or fungal.

After additional refinements, the new technique was able to achieve a 3.5-fold increase in sequencing throughput, allowing pathogen identification within minutes after sequencing began. In fact, the highest quality results were generated within 2 or 3 hours of the beginning of sequencing. In contrast, with Illumina the final results are available only after the sequencing is finished. "This new system might facilitate same-shift adaption of antibiotic intervention at the ICU, which might, in turn, improve patient outcomes significantly,"suggested Sohn. In an additional retrospective analysis of 239 samples taken from sepsis patients, however, the accuracy of nanopore sequencing was lower than with Illumina (85% vs. 99%).

"Time consuming, error- and contamination-prone blood cultures are still considered as the standard of care for sepsis diagnostics, frequently leading to an inappropriate and delayed targeted therapy," said Prof. Dr. Brenner. "The nanopore sequencing platform sequences in real time and has the potential to reduce time to diagnosis to only a few hours."

As with every DNA-based method, however, researchers are only able to get information about antibiotic resistance genes, that is which antibiotics won't be effective. To know which antibiotics actually are effective they'd need confirmatory culture-based methods.

Read this article:
German and UK researchers cut time to sepsis diagnosis - European Biotechnology

Read More...

Vir Biotechnology, Inc. (VIR) distance from 20-day Simple moving Average is 76.19% : What to Expect? – The InvestChronicle

Friday, March 6th, 2020

At the end of the latest market close, Vir Biotechnology, Inc. (VIR) was valued at $40.97. In that particular session, Stock kicked-off at the price of $42 while reaching the peak value of $47.47 and lowest value recorded on the day was $41.71. The stock current value is $44.90.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -40.13% during the 52-week period from high price, and 285.39% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.07 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 257.06%, having the revenues showcasing 240.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 6.38B, as it employees total of 217 workers.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 52.22%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 48.91%. In the last 20 days, the companys Stochastic %K was 46.74% and its Stochastic %D was recorded 50.97%.

If we look into the earlier routines of Vir Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 257.06%. The shares increased approximately by 1.54% in the 7-day charts and went down by 28.38% in the period of the last 30 days. Common stock shares were driven by 240.15% during last recorded quarter.

Read more from the original source:
Vir Biotechnology, Inc. (VIR) distance from 20-day Simple moving Average is 76.19% : What to Expect? - The InvestChronicle

Read More...

Global Single-use Bioprocessing Material Market Key Players Profiled Applikon Biotechnology BV, Cesco Bioengineering Co. Ltd., GE Healthcare ,…

Friday, March 6th, 2020

The Global Single-use Bioprocessing Material Market by Product Type (Plastic, Silicone and Other) and by End-Users/Application (Life Science RD and Academic Research Institutes, Biopharmaceutical Manufacturers, Contract Research Organization and Other) Global Market Share, Forecast Data, In-Depth Analysis, and Detailed Overview, and Forecast, 2015 2027 report has been added to ProficientMarket.coms offering.

In the recent years single-use technologies have evolved to become a mainstream approach for achieving productivity. Generally, Single-use Bioprocessing Material Market consists of disposable products that assist in manufacturing biopharmaceutical products. Moreover, these products have also proved to be beneficial for the small scale pharmaceutical manufacturers. Therefore, most of the biopharmaceutical companies utilize single-use bioprocessing technology for manufacturing vaccines, monoclonal antibodies, and other pharmaceutical components on a commercial scale.

In terms of revenue, Global Single-use Bioprocessing Material Market in 2018 stood at USD XX million and is expected to reach USD XX million by 2026 growing at a CAGR of 17.95% from 2019 to 2026.

Read the full Global Single-use Bioprocessing Material Market Report: https://proficientmarket.com/report/1083/global-single-use-bioprocessing-material-market

Some of the global major players operating in the Single-use Bioprocessing Material market include: Applikon Biotechnology B.V., Cesco Bioengineering Co. Ltd., GE Healthcare (General Electric Company), Sartorius Stedim Biotech S.A, Thermo Fisher Scientific, 3M Company, Eppendorf AG, Finesse Solutions, Inc., Others.

Drivers for the Global Single-use Bioprocessing Material Market: Growth of this market is propelled by rise in adoption of single use technologies across pharmaceutical manufacturing facilities, low risk of product cross contamination, cost-effectiveness, less floor space requirement, high energy efficiency, low water usage, container or closure systems, mixing systems, fermentation systems, and cell culture systems and faster to implement are the key drivers for the growth of the global single use bioprocessing market.

Opportunities for the Global Single-use Bioprocessing Material Market: This market has great opportunities in construction of media bags along with the films used in the bioprocess containers. Additionally, emerging markets such as Brazil, China, and India provide new growth opportunities to players in the single-use bioprocessing market.

Restrains for the Global Single-use Bioprocessing Material Market: On the other hand, extractability and leachability issues regarding disposable components like plastic bags, and environmental and economic concerns are the major factors that are restraining the growth of the single use bioprocessing market.

Get Free Sample PDF (including full TOC, Tables and Figures) of Single-use Bioprocessing Material Market @ https://proficientmarket.com/sample/1083

Region Wise, Global Single-use Bioprocessing Material Market Analysis: Can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, Asia Pacific leads the Global Single-use Bioprocessing Material Market share due to improving R&D infrastructure, rising focus of market players, and increasing government initiatives as well as significant growth of pharmaceutical and the biotechnology industries across the countries of Asia-Pacific region which is followed by the North America and Europe.

Global Single-use Bioprocessing Material Market: Product analysisPlasticSiliconeOther

On the basis of type, Plastic accounted for largest share of total revenue generated. Because of their large use in manufacturing of polyethylene.

Global Single-use Bioprocessing Material Market: Application analysisLife Science RD and Academic Research InstitutesBiopharmaceutical ManufacturersContract Research OrganizationOther

The demand of Global Single-use Bioprocessing Material Market is highest from Biopharmaceutical Manufacturers, due to high energy efficiency, low water usage, less floor space requirement and very low risk of product cross contamination.

Global Single-use Bioprocessing Material Market: Region analysisNorth America: U.S., Canada, MexicoEurope: U.K., France, Germany, Spain, Italy, Rest of EuropeAsia Pacific: China, Japan, South Korea, ASEAN, IndiaRest of Asia Pacific: Latin America, Brazil, Argentina, Colombia, Rest of L.A.Middle East and Africa: Turkey, GCC, UAE, South Africa, Rest of Middle East

The report can be customized as per client requirements. For further queries, you can contact us on [emailprotected] or +1-773-800-2974. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Read the full press release and latest news of this reports, here: https://proficientmarket.com/press-release/1083/global-single-use-bioprocessing-material-market

About Us:

Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialist with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever new fun research methods developed by our team.

Contact Us:

Proficient Market1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 IndiaTel: +91-8149441100 (GMT Office Hours)USA: +17738002974Email: [emailprotected]Web: proficientmarket.com

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

See more here:
Global Single-use Bioprocessing Material Market Key Players Profiled Applikon Biotechnology BV, Cesco Bioengineering Co. Ltd., GE Healthcare ,...

Read More...

Media, Sera and Reagents in Biotechnology Market Research, Recent Trends and Gro – News by aeresearch

Tuesday, February 11th, 2020

This report describes a study of the Media, Sera and Reagents in Biotechnology market for the evaluation period 2025. It also incorporates a Media, Sera and Reagents in Biotechnology market growth factor analysis comprising Porters five-factor analysis and supply chain analysis. A segmental breakdown of the market is added for a greater understanding of the market mechanism.

Latest Report onMedia, Sera and Reagents in Biotechnology Market size | Industry Segment by Applications (Cancer Research, Virology, Toxicity Testing, Vaccine Production and Drug Development), by Type (Media, Sera and Reagents), Regional Outlook, Market Demand, Latest Trends, Media, Sera and Reagents in Biotechnology Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report holds a granular analysis of the Media, Sera and Reagents in Biotechnology industry situations, market demands, the report provides in-depth Media, Sera and Reagents in Biotechnology market analysis and data according to classifications such as types, Application/end user, regional, company and competitive environment. A broad analysis has been done on Media, Sera and Reagents in Biotechnology market share of all the segments. The report also includes review of recent development in Media, Sera and Reagents in Biotechnology market. The report also explores detailed picture of growth drivers and inhibitors of the global Media, Sera and Reagents in Biotechnology market.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/77508

Report Scope:

The study includes the profiles of key players in the Media, Sera and Reagents in Biotechnology market with a significant global and/or regional presence. The Media, Sera and Reagents in Biotechnology market competition by top Manufacturers Covers:

Media, Sera and Reagents in Biotechnology Market Outlook by Applications:

Media, Sera and Reagents in Biotechnology Market Statistics by Types:

The Media, Sera and Reagents in Biotechnology Market report demonstrates growth trends and future opportunities at geographic level. This report helps in understanding the global Media, Sera and Reagents in Biotechnology Market trends in the industry and develop schemes to be executed in the future. Furthermore, the Media, Sera and Reagents in Biotechnology Market research report summarizes some of the leading enterprises in the Media, Sera and Reagents in Biotechnology industry. It mentions their strategic initiatives and offers a brief about their business.

The study on the global Media, Sera and Reagents in Biotechnology market includes qualitative factors such as drivers, restraints, and opportunities. The study covers the qualitative and quantitative analysis of the market segmented based on type, technology, and vertical. Moreover, the study provides similar information for the key geographies.

The Media, Sera and Reagents in Biotechnology Analysis report offers an entire substantial study of the Media, Sera and Reagents in Biotechnology market, key tactics followed by leading Media, Sera and Reagents in Biotechnology industry Players and impending segments. The previous and current Media, Sera and Reagents in Biotechnology industry forecast analysis in terms of volume and value along with research conclusions is a decisive part of Media, Sera and Reagents in Biotechnology market analysis report.

Objective of Studies of Media, Sera and Reagents in Biotechnology Market:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/77508

Read more from the original source:
Media, Sera and Reagents in Biotechnology Market Research, Recent Trends and Gro - News by aeresearch

Read More...

What to Analyze About the Vir Biotechnology (VIR)? – News Welcome

Tuesday, February 11th, 2020

Vir Biotechnology (VIR) stock traded 202182 shares in most recent trading session as compared to an average volume of 303.69K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. Shares of the Vir Biotechnology (VIR) moved down -2.20% to trade at $20.02 on Monday trading session. It has a market capitalization of $2.06B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock EPS is $-1.26 against its recent stock value of $20.02 per share.

First we will be looking for the boiling points and excitability of Vir Biotechnology (VIR) stock, it purposes common trait for traders and value investors.

Volatility Indicators for Vir Biotechnology:

Volatility of the Vir Biotechnology remained at 8.68% over last week and shows 13.10% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 2.45.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -12.21% during the period of last 5 trading days. The stock maintained for the month at 58.39%. The stock noted year to date 2019 performance at 59.20% and changed about 37.78% over the last three months. The stock is now standing at -30.97% from 52 week-high and is situated at 71.84% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 54.23.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently up 4.61% from its 20 days moving average and trading 31.75% above the 50 days moving average. The stock price has been seen performing along overhead drift from its 200 days moving average with 36.06%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Profitability Spotlight for Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

The price-to-earnings ratio or P/E is one of the most widely-used stock analysis tools to determine a stocks valuation

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.4 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.33.

See the original post:
What to Analyze About the Vir Biotechnology (VIR)? - News Welcome

Read More...

Page 35«..1020..34353637..4050..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick